KR20140144200A - Ccr3-억제제의 용도 - Google Patents

Ccr3-억제제의 용도 Download PDF

Info

Publication number
KR20140144200A
KR20140144200A KR1020147027679A KR20147027679A KR20140144200A KR 20140144200 A KR20140144200 A KR 20140144200A KR 1020147027679 A KR1020147027679 A KR 1020147027679A KR 20147027679 A KR20147027679 A KR 20147027679A KR 20140144200 A KR20140144200 A KR 20140144200A
Authority
KR
South Korea
Prior art keywords
eosinophilic
formula
chloride
gastritis
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147027679A
Other languages
English (en)
Korean (ko)
Inventor
마이클 채덤 니벤스
티에리 부이수
롤프 괴겔
페터 자이터
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48040249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20140144200(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Publication of KR20140144200A publication Critical patent/KR20140144200A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Structure Of Transmissions (AREA)
KR1020147027679A 2012-04-03 2013-04-02 Ccr3-억제제의 용도 Ceased KR20140144200A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12162937.2 2012-04-03
EP12162937 2012-04-03
PCT/EP2013/056864 WO2013149986A1 (en) 2012-04-03 2013-04-02 Use of ccr3-inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207011392A Division KR20200044988A (ko) 2012-04-03 2013-04-02 Ccr3-억제제의 용도

Publications (1)

Publication Number Publication Date
KR20140144200A true KR20140144200A (ko) 2014-12-18

Family

ID=48040249

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020147027679A Ceased KR20140144200A (ko) 2012-04-03 2013-04-02 Ccr3-억제제의 용도
KR1020207011392A Ceased KR20200044988A (ko) 2012-04-03 2013-04-02 Ccr3-억제제의 용도
KR1020257028220A Pending KR20250133980A (ko) 2012-04-03 2013-04-02 Ccr3-억제제의 용도
KR1020227031439A Ceased KR20220132012A (ko) 2012-04-03 2013-04-02 Ccr3-억제제의 용도
KR1020217015686A Ceased KR20210063481A (ko) 2012-04-03 2013-04-02 Ccr3-억제제의 용도

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020207011392A Ceased KR20200044988A (ko) 2012-04-03 2013-04-02 Ccr3-억제제의 용도
KR1020257028220A Pending KR20250133980A (ko) 2012-04-03 2013-04-02 Ccr3-억제제의 용도
KR1020227031439A Ceased KR20220132012A (ko) 2012-04-03 2013-04-02 Ccr3-억제제의 용도
KR1020217015686A Ceased KR20210063481A (ko) 2012-04-03 2013-04-02 Ccr3-억제제의 용도

Country Status (28)

Country Link
US (5) US20130261153A1 (https=)
EP (3) EP4389217A3 (https=)
JP (2) JP2015512432A (https=)
KR (5) KR20140144200A (https=)
CN (2) CN104220073A (https=)
AU (1) AU2013245027B2 (https=)
BR (1) BR112014023795B1 (https=)
CA (1) CA2869269C (https=)
CL (1) CL2014002523A1 (https=)
CY (1) CY1123222T1 (https=)
DK (1) DK2833884T3 (https=)
EA (1) EA032263B1 (https=)
ES (2) ES2811554T3 (https=)
HR (1) HRP20201165T1 (https=)
HU (1) HUE051648T2 (https=)
IL (1) IL234262A (https=)
IN (1) IN2014DN06989A (https=)
LT (1) LT2833884T (https=)
MX (1) MX2014011786A (https=)
NZ (1) NZ628882A (https=)
PH (1) PH12014502239A1 (https=)
PL (1) PL2833884T3 (https=)
PT (1) PT2833884T (https=)
RS (1) RS60665B1 (https=)
SI (1) SI2833884T1 (https=)
SM (1) SMT202000499T1 (https=)
WO (1) WO2013149986A1 (https=)
ZA (1) ZA201406082B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190008571A (ko) 2016-11-24 2019-01-24 가부시키가이샤 키리시마 세이코 치열 교정기, 및 치열 교정기 설치 방법
KR20190131121A (ko) * 2017-04-05 2019-11-25 알카헤스트 인코포레이티드 Ccr3-저해제를 사용하여 망막-관련 질병을 치료하는 방법 및 조성물

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
SG11201909245PA (en) 2017-04-05 2019-11-28 Alkahest Inc Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
CA3076017A1 (en) * 2017-10-13 2019-04-18 Alkahest, Inc. Methods and compositions for treating pruritus, xerosis, and associated disease using ccr3-inhibitors
MY198220A (en) 2018-05-15 2023-08-14 Alkahest Inc Treatment Of Aging-Associated Disease With Modulators Of Leukotriene A4 Hydrolase
CN112789044A (zh) * 2018-09-26 2021-05-11 万能溶剂有限公司 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物
AU2021287906B2 (en) 2020-06-11 2025-09-11 Alkahest Inc. Methods of improving retina-associated disease outcome using CCR3-inhibitors
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
BRPI0108923B8 (pt) * 2000-03-03 2021-05-25 Cambridge Antibody Tech Limited elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
US8030003B2 (en) * 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
US8008092B2 (en) * 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
WO2010069979A1 (en) * 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
WO2010138591A1 (en) * 2009-05-26 2010-12-02 University Of Kentucky Research Foundation Ccr3 and its ligands are therapeutic and diagnostic targets for neovascular age-related macular degeneration
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2020115836A1 (ja) * 2018-12-05 2020-06-11 東浜工業株式会社 ブロワー装置

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190008571A (ko) 2016-11-24 2019-01-24 가부시키가이샤 키리시마 세이코 치열 교정기, 및 치열 교정기 설치 방법
KR20190131121A (ko) * 2017-04-05 2019-11-25 알카헤스트 인코포레이티드 Ccr3-저해제를 사용하여 망막-관련 질병을 치료하는 방법 및 조성물

Also Published As

Publication number Publication date
BR112014023795A2 (https=) 2017-06-20
EA201401083A1 (ru) 2015-03-31
EP2833884B1 (en) 2020-05-20
KR20220132012A (ko) 2022-09-29
IN2014DN06989A (https=) 2015-04-10
DK2833884T3 (da) 2020-08-10
PL2833884T3 (pl) 2020-11-02
CY1123222T1 (el) 2021-10-29
HUE051648T2 (hu) 2021-03-29
JP2018080183A (ja) 2018-05-24
SMT202000499T1 (it) 2020-11-10
AU2013245027A1 (en) 2014-09-11
WO2013149986A1 (en) 2013-10-10
EP2833884A1 (en) 2015-02-11
AU2013245027B2 (en) 2017-10-12
KR20200044988A (ko) 2020-04-29
US20130261153A1 (en) 2013-10-03
EA032263B1 (ru) 2019-05-31
CN104220073A (zh) 2014-12-17
BR112014023795A8 (pt) 2017-10-10
RS60665B1 (sr) 2020-09-30
CA2869269C (en) 2020-06-30
ES2811554T3 (es) 2021-03-12
PH12014502239A1 (en) 2014-12-15
KR20210063481A (ko) 2021-06-01
NZ628882A (en) 2016-05-27
EP3763369A1 (en) 2021-01-13
KR20250133980A (ko) 2025-09-09
EP3763369B1 (en) 2024-02-28
JP2015512432A (ja) 2015-04-27
ZA201406082B (en) 2019-01-30
ES2987267T3 (es) 2024-11-14
PT2833884T (pt) 2020-08-26
IL234262A (en) 2017-10-31
EP4389217A2 (en) 2024-06-26
SI2833884T1 (sl) 2020-10-30
LT2833884T (lt) 2020-09-10
CL2014002523A1 (es) 2015-01-23
CN110384699A (zh) 2019-10-29
US20170319567A1 (en) 2017-11-09
EP4389217A3 (en) 2024-08-28
HRP20201165T1 (hr) 2020-12-11
CA2869269A1 (en) 2013-10-10
MX2014011786A (es) 2014-12-05
US20150099783A1 (en) 2015-04-09
US20160081998A1 (en) 2016-03-24
US20200375971A1 (en) 2020-12-03
BR112014023795B1 (pt) 2021-09-08

Similar Documents

Publication Publication Date Title
EP3763369B1 (en) Use of ccr3-inhibitors for treating dry age-related macular degeneration
JP6700332B2 (ja) Ｃｃｒ３アンタゴニストを含む医薬製剤
JP4394686B2 (ja) 唾液分泌促進用医薬組成物およびその使用
HK40015701A (en) Use of ccr3-inhibitors
AU2006283702A1 (en) Comination of a hypnotic agent and R(+)-alpha-(2,3-dimethoxy-phenyl)-1-(2-(4-fluorophenl)ethyl)-4-piperidinemethanol and therapeutic application thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140930

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20171107

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180330

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190401

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20191125

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190401

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20191125

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190628

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180330

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20200319

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200224

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20191125

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190628

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20190401

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180330

X601 Decision of rejection after re-examination
A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200420

PJ0201 Trial against decision of rejection

Patent event date: 20200420

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20200319

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20191125

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20210628

Appeal identifier: 2020101001132

Request date: 20200420

J301 Trial decision

Free format text: TRIAL NUMBER: 2020101001132; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20200420

Effective date: 20210628

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20210628

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20200420

Decision date: 20210628

Appeal identifier: 2020101001132